Acute Myeloid Leukemia Clinical Trial
SCT Plus Immune Therapy in Average Risk AML/MDS
Reduced intensity conditioning regimen of Busulfan (Bu) and Fludarabine (Flu) + Anti-Thymocyte Globulin (ATG ) (unrelated donors only) or reduced toxicity conditioning regimen of Bu/Flu/alemtuzumab, or reduced hepatic toxicity regimen of melphan/Flu/alemtuzumab and AlloSCT, followed by Gemtuzumab Ozogamicin consolidation in patients with average risk AML/MDS meeting eligibility criteria.
AML 1st CR with a matched family donor
AML 1st CR with unrelated donor
AML 2nd CR or CRP
MDS and < or = 5% bone marrow myeloblasts at diagnosis
Disease must express a minimum of > or = 10% CD33 positivity for patients with AML
Adequate renal function, adequate liver function, adequate cardiac function, adequate pulmonary function
Patients with active CNS AML disease at time of preparative regimen
Female patients who are pregnant
Karnofsky <70% or Lansky <50% if 10 years or less
Age >25 years
Seropositive for HIV
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Valhalla New York, 10595, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.